Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / physiology
-
ATP-Binding Cassette Transporters / physiology*
-
Adenosine Triphosphate / metabolism
-
Antineoplastic Agents / pharmacokinetics
-
Biomarkers
-
Breast Neoplasms / metabolism
-
Drug Design
-
Drug Resistance, Multiple*
-
Drug Resistance, Neoplasm*
-
Female
-
Forecasting
-
Humans
-
Leukemia / metabolism
-
Multidrug Resistance-Associated Proteins / chemistry
-
Multidrug Resistance-Associated Proteins / classification
-
Multidrug Resistance-Associated Proteins / genetics
-
Multidrug Resistance-Associated Proteins / physiology*
-
Multigene Family
-
Neoplasm Proteins / physiology
-
Neoplasms / drug therapy
-
Neoplasms / metabolism
-
Organ Specificity
-
Permeability
-
Structure-Activity Relationship
-
Xenobiotics / adverse effects
-
Xenobiotics / pharmacokinetics
Substances
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
ATP-Binding Cassette Transporters
-
Antineoplastic Agents
-
Biomarkers
-
Multidrug Resistance-Associated Proteins
-
Neoplasm Proteins
-
Xenobiotics
-
Adenosine Triphosphate